SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?


To: bumblin bob who wrote (193382)5/18/2009 11:46:40 AM
From: BarbaraT  Read Replies (2) | Respond to of 208838
 
MNKD MannKind announces FDA accepts submission and files NDA for AFRESA (6.90 +1.00)

Co announces the FDA has accepted and filed MannKind's New Drug Application for AFRESA, an ultra rapid-acting insulin. MannKind is seeking FDA approval of AFRESA for the treatment of adults with type 1 or type 2 diabetes mellitus for the control of hyperglycemia.